Pure Form IV Benzamide Crystallization for Polymorphic Stability

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for a composition containing essentially pure Form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide for treating tumors, cancers, or Rasopathy disorders, as compositions with multiple polymorphic forms can lead to interconversion issues affecting efficacy and stability.

Innovation Solution

A crystalline composition of essentially pure Form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide is developed, characterized by a specific XRPD pattern and DSC profile, which remains unchanged after long-term storage, ensuring stability and purity, and is formulated into pharmaceutical compositions for oral administration.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of manufacture

If compositions containing multiple polymorphic forms are used, then manufacturing is easier, but polymorphic interconversion occurs leading to instability and inconsistent efficacy

Engineering Contradiction:

Improveease of manufactureVSAvoidcompositional stability

Core Design Contradiction:

Ease of manufactureVSStability of the object's composition

Solution Approach 1:

The patent extracts and isolates only the desired polymorphic Form IV from mixed polymorphic compositions through selective crystallization and purification processes. This removes the harmful presence of other polymorphic forms that cause interconversion, while maintaining the manufacturing advantages of working with crystalline materials.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent employs parameter changes in the crystallization process (temperature, solvent composition, pH, addition rate) to selectively produce and stabilize polymorphic Form IV. By controlling these parameters, the composition remains stable and prevents interconversion to other polymorphic forms during storage and processing.

Inventive Principle:

Principle #35Parameter changes

2Adaptability or versatility

If polymorphic interconversion is allowed to occur, then the system remains flexible, but effective dose and physical properties vary affecting treatment consistency

Engineering Contradiction:

Improvepolymorphic flexibilityVSAvoidtreatment consistency

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent applies preliminary anti-action by pre-stabilizing the composition as pure polymorphic Form IV before storage and use. This preemptive measure prevents interconversion from occurring during storage, ensuring that the effective dose and physical properties remain consistent throughout the product lifecycle.

Inventive Principle:

Principle #9Preliminary anti-action

Solution Approach 2:

The patent performs preliminary purification and stabilization actions during manufacturing to ensure the final product contains essentially pure polymorphic Form IV. This preliminary action establishes compositional stability that persists through storage and handling, guaranteeing treatment consistency.

Inventive Principle:

Principle #10Preliminary action

3Duration of action of moving object

If longer storage periods are required, then patient compliance improves, but polymorphic stability may deteriorate over time

Engineering Contradiction:

Improvestorage durationVSAvoidpolymorphic stability

Core Design Contradiction:

Duration of action of moving objectVSStability of the object's composition

Solution Approach 1:

The patent provides beforehand cushioning by formulating the composition as stable polymorphic Form IV with appropriate excipients and storage conditions specified. This protective formulation approach cushions against potential degradation or interconversion during extended storage periods, maintaining stability throughout the product shelf life.

Inventive Principle:

Principle #11Beforehand cushioning (Prior cushioning)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The crystalline composition maintains stability and purity over extended storage periods, ensuring consistent therapeutic efficacy and reducing the risk of polymorphic interconversion, thereby providing a reliable treatment for tumors, cancers, and Rasopathy disorders.

Implementation Method 1

Methodology Applied

Scientific EffectCrystalline structure stability:

Data Source

PatentUS20250002449A1Compositions of essentially pure form iv of n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof

Publication Date: 2025.01.02 WARNER LAMBERT CO LLC

AI summary

The present disclosure relates to: a) a crystalline composition of essentially pure Form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide; b) pharmaceutical compositions comprising the crystalline composition of essentially pure Form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, and, optionally, a pharmaceutically acceptable carrier; and c) methods of treating a tumor, a cancer, or a Rasopathy disorder by administering the crystalline composition of essentially pure Form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide to a subject in need thereof.